BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

  Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study.

  September 19, 2021

   · 

  11 min read
• BioForest

  Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

  Seagen Inc. and Genmab A/S presented interim data from two cohorts of the phase 1b/2 innovaTV 205 multi-cohort, open-label trial of tisotumab vedotin in recurrent or metastatic cervical cancer at the European Society for Medical Oncology Virtual Congress 2021 as part of a featured mini oral presentation.

  September 19, 2021

   · 

  13 min read
• Biotech Beach

  Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

  Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain, autoimmune disease and COVID-19, announced impressive results from an independent study conducted under real-world field conditions by INMEGEN.

  September 19, 2021

   · 

  5 min read
• Pharm Country

  HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

  HUTCHMED Limited announces that it has initiated a Japan registration-enabling bridging study for surufatinib to support the registration of surufatinib in the treatment of patients with advanced neuroendocrine tumors.

  September 19, 2021

   · 

  9 min read
• Appealing Data of CARsgen Therapeutics’ CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

  On September 19, 2021, CARsgen Therapeutics disclosed the latest progress of the investigator-initiated trial of Claudin18.2 CAR-T for the treatment of digestive system tumors.

  September 19, 2021

   · 

  7 min read